secwatch / observer
8-K filed March 29, 2024, 7:59 PM ET ticker IOVA CIK 0001425205
leadership confidence high sentiment neutral materiality 0.35

Iovance Biotherapeutics director McPeak to retire; interim CEO Vogt nominated to board

IOVANCE BIOTHERAPEUTICS, INC.

item 5.02item 5.03item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Frederick G. Vogt

Director
IOVA · IOVANCE BIOTHERAPEUTICS, INC.
Filed
March 29, 2024, 7:59 PM ET
Frederick G. Vogt, Ph.D., J.D., the Company’s Interim Chief Executive Officer and President, and General Counsel, be nominated to stand for election to the Board at the Annual Meeting
Departed

Merrill A. McPeak

Director
IOVA · IOVANCE BIOTHERAPEUTICS, INC.
Successor
Frederick G. Vogt
Filed
March 29, 2024, 7:59 PM ET
General (Ret.) Merrill A. McPeak, a member of the Board of Directors (the “ Board ”) of Iovance Biotherapeutics, Inc. (the “ Company ”), provided notice to the Board that he will retire and not be standing for re-election to the Board at the Company’s annual meeting

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Frederick G. Vogt was appointed as Director at IOVANCE BIOTHERAPEUTICS, INC..

Action
nominated to stand for election
Role
Director
Exact text from the filing
Frederick G. Vogt, Ph.D., J.D., the Company’s Interim Chief Executive Officer and President, and General Counsel, be nominated to stand for election to the Board at the Annual Meeting
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Merrill A. McPeak retired as Director at IOVANCE BIOTHERAPEUTICS, INC..

Action
retired
Role
Director
Exact text from the filing
General (Ret.) Merrill A. McPeak, a member of the Board of Directors (the “ Board ”) of Iovance Biotherapeutics, Inc. (the “ Company ”), provided notice to the Board that he will retire and not be standing for re-election to the Board at the Company’s annual meeting
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

IOVANCE BIOTHERAPEUTICS, INC.: Amended and restated bylaws to modify the definition of 'Acting in Concert' (effective 2024-03-28).

Change
bylaw amendment
Effective
2024-03-28
Exact text from the filing
On March 28, 2024, the Board unanimously adopted the Company’s Fourth Amended and Restated Bylaws
View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR
accession 0001104659-24-041200
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.